[A18-55] Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V
Last updated 03.12.2018
Commission awarded on 03.09.2018 by the Federal Joint Committee (G-BA).
Skin and hair
Patients with non-hyperkeratotic, non-hypertrophic actinic keratosis
Actinic keratosis on face or scalp: hint of non-quantifiable (at most considerable) added benefit; on trunk or extremeties: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-02||Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55||Commission completed|
|A13-04||Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)||Commission completed|